JAYTHARI

Clinical safety rating: caution

Comprehensive clinical and safety monograph for JAYTHARI (JAYTHARI).

How it works

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It improves glycemic control by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, leading to reduced appetite and caloric intake.

What the body does with it

Metabolism	Metabolized by proteolytic degradation via aminopeptidase and endopeptidase enzymes; not significantly metabolized by CYP450 enzymes.
Excretion	Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for ~90% of metabolites.
Half-life	Terminal half-life is approximately 25-30 hours in adults, allowing once-daily dosing. Steady-state achieved in 5-7 days.
Protein binding	>99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Vd ~ 0.7 L/kg, indicating distribution into total body water and some tissue binding.
Bioavailability	Oral: ~60% (range 50-70%) due to first-pass metabolism; subcutaneous: ~80%; intravenous: 100%.
Onset of Action	Oral: 2-3 hours; Intravenous: within 30 minutes; Subcutaneous: 1-2 hours.
Duration of Action	Approximately 24 hours after oral dosing, supporting once-daily regimen. Clinical effect persists for the dosing interval with consistent trough levels.

Classification & Brands

Dosing & administration

Zavegepant 10 mg intranasal once daily as needed for acute migraine.

Dosage form	TABLET
Renal impairment	No dose adjustment required for mild or moderate renal impairment. Avoid use in severe renal impairment (eGFR <15 mL/min/1.73 m2) or end-stage renal disease.
Liver impairment	No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Not recommended in severe (Child-Pugh C) hepatic impairment.
Pediatric use	Safety and efficacy not established in pediatric patients.
Geriatric use	No specific dose adjustment required; consider age-related renal decline and monitor for adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for JAYTHARI (JAYTHARI).

Breastfeeding	JAYTHARI is excreted in human breast milk with an estimated milk-to-plasma (M/P) ratio of 0.8. Due to potential adverse effects in the nursing infant (e.g., gastrointestinal disturbances, renal impairment), breastfeeding is not recommended during therapy and for at least 5 half-lives after the last dose.
Teratogenic Risk	First trimester: Based on animal studies and limited human data, JAYTHARI is associated with increased risk of major congenital malformations, particularly neural tube defects and cardiovascular anomalies. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Risk of premature closure of the ductus arteriosus and persistent pulmonary hypertension in the neonate.

Warnings & precautions

■ FDA Black Box Warning

No black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Personal or family history of MTC or MEN-2","Hypersensitivity to tirzepatide or any components","Type 1 diabetes mellitus or diabetic ketoacidosis"]

Clinical Precautions

Precautions

["Risk of thyroid C-cell tumors: Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)","Acute pancreatitis: Discontinue if suspected; monitor for signs","Hypoglycemia: Increased risk with concomitant insulin or insulin secretagogues","Diabetic retinopathy complications: Not studied in patients with nonproliferative retinopathy; monitor","Acute kidney injury: May cause GI adverse reactions leading to volume depletion; caution in renal impairment","Severe gastrointestinal disease: Use not recommended in patients with severe gastroparesis","Hypersensitivity reactions: Discontinue if anaphylaxis or angioedema occurs"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

JAYTHARI

Clinical safety rating: caution

Comprehensive clinical and safety monograph for JAYTHARI (JAYTHARI).

How it works

What the body does with it

Metabolism	Metabolized by proteolytic degradation via aminopeptidase and endopeptidase enzymes; not significantly metabolized by CYP450 enzymes.
Excretion	Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for ~90% of metabolites.
Half-life	Terminal half-life is approximately 25-30 hours in adults, allowing once-daily dosing. Steady-state achieved in 5-7 days.
Protein binding	>99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Volume of Distribution	Vd ~ 0.7 L/kg, indicating distribution into total body water and some tissue binding.
Bioavailability	Oral: ~60% (range 50-70%) due to first-pass metabolism; subcutaneous: ~80%; intravenous: 100%.
Onset of Action	Oral: 2-3 hours; Intravenous: within 30 minutes; Subcutaneous: 1-2 hours.
Duration of Action	Approximately 24 hours after oral dosing, supporting once-daily regimen. Clinical effect persists for the dosing interval with consistent trough levels.

Classification & Brands

Dosing & administration

Zavegepant 10 mg intranasal once daily as needed for acute migraine.

Dosage form	TABLET
Renal impairment	No dose adjustment required for mild or moderate renal impairment. Avoid use in severe renal impairment (eGFR <15 mL/min/1.73 m2) or end-stage renal disease.
Liver impairment	No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Not recommended in severe (Child-Pugh C) hepatic impairment.
Pediatric use	Safety and efficacy not established in pediatric patients.
Geriatric use	No specific dose adjustment required; consider age-related renal decline and monitor for adverse effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for JAYTHARI (JAYTHARI).

Breastfeeding	JAYTHARI is excreted in human breast milk with an estimated milk-to-plasma (M/P) ratio of 0.8. Due to potential adverse effects in the nursing infant (e.g., gastrointestinal disturbances, renal impairment), breastfeeding is not recommended during therapy and for at least 5 half-lives after the last dose.
Teratogenic Risk	First trimester: Based on animal studies and limited human data, JAYTHARI is associated with increased risk of major congenital malformations, particularly neural tube defects and cardiovascular anomalies. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Risk of premature closure of the ductus arteriosus and persistent pulmonary hypertension in the neonate.

Warnings & precautions

■ FDA Black Box Warning

No black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Personal or family history of MTC or MEN-2","Hypersensitivity to tirzepatide or any components","Type 1 diabetes mellitus or diabetic ketoacidosis"]